ストックスクリーナーアプリを入手
38.26
0.51%
-0.275
前日終値:
$38.53
開ける：
$38.52
24時間の取引高:
394.90K
Relative Volume:
0.10
時価総額：
$16.34B
収益：
$2.31B
当期純損益:
$1.66B
株価収益率:
16.65
EPS:
2.297
ネットキャッシュフロー:
$827.02M
1週間 パフォーマンス:
+0.64%
1か月 パフォーマンス:
-2.11%
6か月 パフォーマンス:
+9.22%
1年 パフォーマンス:
+53.34%
1日の値動き範囲:
$38.23
$38.66
1週間の範囲:
$37.88
$38.93
52週間の値動き範囲:
$24.05
$41.24
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
RPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
38.26 | 16.46B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.75 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.75 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
849.46 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.47 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
201.09 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-30 | 開始されました | Goldman | Buy |
| 2025-05-16 | 開始されました | Morgan Stanley | Overweight |
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Royalty Pharma stock rises after acquiring cancer drug royalties - Investing.com India
Royalty Pharma Acquires Royalty Interest in Nuvalent's Potential Lung Cancer Therapies - marketscreener.com
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million - The Manila Times
Royalty Pharma acquires royalty interest in cancer drugs for $315 million - Investing.com
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - Quiver Quantitative
Royalty Pharma acquires drug royalty rights for up to $315 million - StreetInsider
Royalty Pharma (Nasdaq: RPRX) buys Nuvalent NSCLC royalties for up to $315M - Stock Titan
Squarepoint Ops LLC Makes New $9.85 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Eventide Asset Management LLC Buys 41,830 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Adage Capital Partners GP L.L.C. Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Main Street Financial Solutions LLC Buys 31,844 Shares of Royalty Pharma PLC $RPRX - MarketBeat
TD Cowen raises Royalty Pharma stock price target on growth outlook By Investing.com - Investing.com South Africa
Precision Trading with Royalty Pharma Plc (RPRX) Risk Zones - news.stocktradersdaily.com
TD Cowen Forecasts Strong Price Appreciation for Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
RPRX: TD Cowen Raises Price Target for Royalty Pharma | RPRX Sto - GuruFocus
TD Cowen raises Royalty Pharma stock price target on growth outlook - Investing.com Nigeria
Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' - StreetInsider
First Trust Advisors LP Has $39.78 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
California Public Employees Retirement System Sells 268,263 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Sells $913,526.10 in Stock - MarketBeat
Hsbc Holdings PLC Sells 77,498 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Holdings Raised by Amundi - MarketBeat
Denali enters into a $275M funding deal with Royalty Pharma - MSN
What Royalty Pharma (RPRX)'s Denali Rare-Disease Royalty Deal and Cash Surge Means For Shareholders - Sahm
Royalty Pharma (NASDAQ:RPRX) EVP Sells $4,374,700.00 in Stock - MarketBeat
11% Of This Royalty Pharma Insider's Holdings Were Sold - 富途牛牛
Royalty Pharma Insider Sold Shares Worth $4,375,008, According to a Recent SEC Filing - marketscreener.com
What's Going On With Denali Therapeutics Stock Friday?Denali Therapeutics (NASDAQ:DNLI) - Benzinga
Royalty Pharma (RPRX): Assessing Valuation After a Strong Multi‑Month Share Price Rally - Sahm
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Prime Publishers, Inc.
Is It Too Late to Reassess Royalty Pharma After Its 52% Surge in 2025? - Yahoo Finance
Royalty Pharma PLC $RPRX Shares Acquired by Schroder Investment Management Group - MarketBeat
Denali makes $275m funding agreement with Royalty Pharma - Yahoo Finance
Will Royalty Pharma plc (RPD) stock maintain strong growth2025 Valuation Update & Reliable Volume Spike Trade Alerts - Newser
Royalty Pharma (NASDAQ:RPRX) CFO Sells $2,774,234.34 in Stock - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $931,686.69 in Stock - MarketBeat
Is Royalty Pharma plc stock a good choice for value investors2025 Market Sentiment & Verified Technical Trade Signals - Newser
Denali Therapeutics stock rises on $275 million royalty deal with Royalty Pharma - Investing.com Australia
Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement - Nasdaq
Denali Therapeutics and Royalty Pharma ink $275 million funding deal By Investing.com - Investing.com Nigeria
Royalty Pharma, Denali Sign $275 Million Hunter Syndrome Treatment Royalty Deal - marketscreener.com
Denali Therapeutics and Royalty Pharma ink $275 million funding deal - Investing.com
Denali Therapeutics enters $275 million royalty funding agreement with Royalty Pharma - Investing.com
How Royalty Pharma plc (RPD) stock correlates with oil marketsMarket Activity Summary & Capital Efficiency Focused Strategies - Newser
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Agreement for Tividenofusp Alfa Development - Quiver Quantitative
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement - The Manila Times
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement - The Manila Times
Denali Therapeutics (Nasdaq: DNLI) lands $275M, 9.25% tividenofusp alfa royalty deal - Stock Titan
OMERS ADMINISTRATION Corp Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc (RPD) stock attractive post correction2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - Newser
How Royalty Pharma plc (RPD) stock trades pre earningsQuarterly Profit Summary & Weekly High Return Forecasts - Newser
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
Royalty Pharma Plc (RPRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Urist Marshall | EVP, Research & Investments |
Dec 05 '25 |
Sale |
39.15 |
23,334 |
913,591 |
160,000 |
| Urist Marshall | EVP, Research & Investments |
Dec 05 '25 |
Sale |
39.15 |
18,242 |
714,224 |
7,398 |
| Lloyd George W. | EVP, Investments & CLO |
Dec 03 '25 |
Sale |
39.77 |
110,000 |
4,375,008 |
110,000 |
| Coyne Terrance P. | EVP & CFO |
Dec 01 '25 |
Sale |
39.87 |
69,582 |
2,773,956 |
47,260 |
| Urist Marshall | EVP, Research & Investments |
Dec 01 '25 |
Sale |
39.93 |
23,333 |
931,633 |
183,334 |
| Urist Marshall | EVP, Research & Investments |
Dec 01 '25 |
Sale |
39.90 |
18,242 |
727,856 |
25,640 |
0.32%
0.83%
大文字化:
|
ボリューム (24 時間):